» Articles » PMID: 28323995

Renin Phenotypes Characterize Vascular Disease, Autonomous Aldosteronism, and Mineralocorticoid Receptor Activity

Overview
Specialty Endocrinology
Date 2017 Mar 22
PMID 28323995
Citations 26
Authors
Affiliations
Soon will be listed here.
Abstract

Context: Mild cases of autonomous aldosterone secretion may go unrecognized using current diagnostic criteria for primary aldosteronism (PA).

Objective: To investigate whether the inability to stimulate renin serves as a biomarker for unrecognized autonomous aldosterone secretion and mineralocorticoid receptor (MR) activation.

Participants: Six hundred sixty-three normotensive and mildly hypertensive participants, who were confirmed to not have PA using current guideline criteria and were on no antihypertensive medications.

Design: Participants had their maximally stimulated plasma renin activity (PRA) measured while standing upright after sodium restriction. Tertiles of maximally stimulated PRA were hypothesized to reflect the degree of MR activation: lowest PRA tertile = "Inappropriate/Excess MR Activity;" middle PRA tertile = "Intermediate MR Activity;"; and highest PRA tertile = "Physiologic MR Activity." All participants underwent detailed biochemical and vascular characterizations under conditions of liberalized sodium intake, and associations with stimulated PRA phenotypes were performed.

Results: Participants with lower stimulated PRA had greater autonomous aldosterone secretion [higher aldosterone-to-renin ratio (P = 0.002), higher urine aldosterone excretion rate (P = 0.003), higher systolic blood pressure (P = 0.004), and lower renal plasma flow (P = 0.04)] and a nonsignificant trend toward lower serum potassium and higher urine potassium excretion, which became significant after stratification by hypertension status.

Conclusions: In participants without clinical PA, the inability to stimulate renin was associated with greater autonomous aldosterone secretion, impaired vascular function, and suggestive trends in potassium handling that indicate an extensive spectrum of unrecognized MR activation.

Citing Articles

Characterizing the Origins of Primary Aldosteronism.

Brown J, Honzel B, Tsai L, Milks J, Neibuhr Y, Neibuhr Y Hypertension. 2024; 82(2):306-318.

PMID: 39660429 PMC: 11735322. DOI: 10.1161/HYPERTENSIONAHA.124.24153.


Primary hyperaldosteronism secondary to right adrenal hyperplasia with non-functioning left adrenal adenoma elucidated by adrenal vein sampling: A case report with in-depth physiological review on utility of aldosterone renin ratio.

Tuchinsky A, Sardar S, Akkari A, Matarneh A, John G, Ghahramani N Clin Case Rep. 2024; 12(10):e9206.

PMID: 39410964 PMC: 11473671. DOI: 10.1002/ccr3.9206.


Successful treatment of resistant hypertension and severe complications in a 63-year-old man with primary aldosteronism without adrenalectomy: A case report.

Wang A, Ma Q, Mbikyo M, Miao L, Cui N, Fu H Heliyon. 2024; 10(13):e33688.

PMID: 39044991 PMC: 11263627. DOI: 10.1016/j.heliyon.2024.e33688.


Challenges in Diagnosing and Managing the Spectrum of Primary Aldosteronism.

Yang J, McCarthy J, Shah S, Ng E, Shen J, Libianto R J Endocr Soc. 2024; 8(7):bvae109.

PMID: 38887633 PMC: 11181003. DOI: 10.1210/jendso/bvae109.


A comparison of the performance of Ga-Pentixafor PET/CT adrenal vein sampling for subtype diagnosis in primary aldosteronism.

Yin X, Ai K, Luo J, Liu W, Ma X, Zhou L Front Endocrinol (Lausanne). 2024; 15:1291775.

PMID: 38419957 PMC: 10899670. DOI: 10.3389/fendo.2024.1291775.


References
1.
Vaidya A, Underwood P, Hopkins P, Jeunemaitre X, Ferri C, Williams G . Abnormal aldosterone physiology and cardiometabolic risk factors. Hypertension. 2013; 61(4):886-93. PMC: 3615445. DOI: 10.1161/HYPERTENSIONAHA.111.00662. View

2.
Garg R, Hurwitz S, Williams G, Hopkins P, Adler G . Aldosterone production and insulin resistance in healthy adults. J Clin Endocrinol Metab. 2010; 95(4):1986-90. PMC: 2853992. DOI: 10.1210/jc.2009-2521. View

3.
Mulatero P, Stowasser M, Loh K, Fardella C, Gordon R, Mosso L . Increased diagnosis of primary aldosteronism, including surgically correctable forms, in centers from five continents. J Clin Endocrinol Metab. 2004; 89(3):1045-50. DOI: 10.1210/jc.2003-031337. View

4.
Vaidya A, Pojoga L, Underwood P, Forman J, Hopkins P, Williams G . The association of plasma resistin with dietary sodium manipulation, the renin-angiotensin-aldosterone system, and 25-hydroxyvitamin D3 in human hypertension. Clin Endocrinol (Oxf). 2010; 74(3):294-9. PMC: 3059847. DOI: 10.1111/j.1365-2265.2010.03922.x. View

5.
Sang X, Jiang Y, Wang W, Yan L, Zhao J, Peng Y . Prevalence of and risk factors for primary aldosteronism among patients with resistant hypertension in China. J Hypertens. 2013; 31(7):1465-71. DOI: 10.1097/HJH.0b013e328360ddf6. View